ANXA9

Across TCGA pan-cancer cohorts, ANXA9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANXA9 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ANXA9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANXA9 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, COAD, and LGG are the cancer types where ANXA9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.130	0.707	<.001	24	view →
COAD	OS	Median	All	0.184	0.803	<.001	14	view →
LGG	DFS	Median	All	0.110	0.826	<.001	6	view →
BRCA	DFS	Median	All	0.294	0.903	<.001	6	view →
BLCA	DFS	Median	II,III,IV	1.000	0.608	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANXA9–LIHC (OS)

Open the LIHC breakdown →